Andrew G. Reaume - Exton PA, US Michael S. Saporito - Exton PA, US Alexander R. Ochman - Exton PA, US Christopher A. Lipinski - Waterford CT, US
Assignee:
MELIOR DISCOVERY, INC. - Exton PA
International Classification:
A61K 31/513 C07D 239/545 A61P 3/10
US Classification:
514274, 544314
Abstract:
The present invention relates to compounds and pharmaceutically acceptable salts thereof, and compositions comprising the same, that are useful in modulating lyn kinase activity, treating obesity, type II diabetes, metabolic syndrome, and in reducing blood glucose level, weight gain, or fat depot level, or treating a disease or condition associated with the same.
The present invention provides methods of activating IRS-1 and/or AKT and methods of treating or preventing IRS-1- and/or AKT-related disease, condition, or disorder.
Andrew G. Reaume - Exton PA, US Michael S. Saporito - Exton PA, US Alexander R. Ochman - Exton PA, US
International Classification:
A61K 31/513
US Classification:
514274
Abstract:
The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in methods of preventing pancreatic beta cell degeneration or methods of treating a disorder associated with pancreatic beta cell degeneration, such as type I diabetes.
- Exton PA, US Michael S. Saporito - Exton PA, US Alexander R. Ochman - Exton PA, US
International Classification:
A61K 31/513
Abstract:
The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in methods of preventing pancreatic beta cell degeneration or methods of treating a disorder associated with pancreatic beta cell degeneration, such as type I diabetes.
- Exton PA, US Michael S. Saporito - Exton PA, US Alexander R. Ochman - Exton PA, US
International Classification:
A61K 31/513 A61K 9/00 A61K 47/22 A61K 38/28
Abstract:
The present invention provides methods of treating Type I or Type II diabetes in a mammal by administering an effective amount of insulin and an effective amount of a phenoxypyrimidinone compound to the mammal in need of such treatment, and formulations for carrying out the methods.
- Exton PA, US Michael S. Saporito - Exton PA, US Alexander R. Ochman - Exton PA, US
Assignee:
Melior Pharmaceuticals l, Inc. - Exton PA
International Classification:
A61K 31/513 A61K 9/00 A61K 38/28
Abstract:
The present invention provides methods of treating Type I or Type II diabetes in a mammal by administering an effective amount of insulin and an effective amount of a phenoxypyrimidinone compound to the mammal in need of such treatment, and formulations for carrying out the methods.